biostudies-literatureUnknown14Shen ZLung cancer is among the most frequently observed and lethal malignancies globally, and metastasis represents a critical determinant of patient outcomes. PTEN, a well-established tumor suppressor, has emerged as an important regulator in lung cancer progression. However, the molecular mechanism of <i>PTEN</i> gene suppressing lung cancer metastasis lacks deeper exploration. In this research, we identify and characterize LncPTEN1, a novel long non-coding RNA generated from <i>PTEN</i> gene. We show that YTHDC1 promotes the alternative splicing of LncPTEN1, resulting in significantly elevated LncPTEN1 expression in normal lung cells. Clinical analyses across multiple patient cohorts demonstrate that low LncPTEN1 expression strongly correlates with poor patient survival and increased metastasNon-coding RNA research25-37https://www.ebi.ac.uk/biostudies/studies/S-EPMC12167124biostudies-literatureLncPTEN1, a long non-coding RNA generated from &lt;i&gt;PTEN&lt;/i&gt;, suppresses lung cancer metastasis through the regulation of EMT progress.PMC12167124Yin YHou ZShen ZZhong ALiang HZhang CTang XZhao XfalseLncPTEN1, a long non-coding RNA generated from &lt;i&gt;PTEN&lt;/i&gt;, suppresses lung cancer metastasis through the regulation of EMT progress.Lung cancer is among the most frequently observed and lethal malignancies globally, and metastasis represents a critical determinant of patient outcomes. PTEN, a well-established tumor suppressor, has emerged as an important regulator in lung cancer progression. However, the molecular mechanism of <i>PTEN</i> gene suppressing lung cancer metastasis lacks deeper exploration. In this research, we identify and characterize LncPTEN1, a novel long non-coding RNA generated from <i>PTEN</i> gene. We show that YTHDC1 promotes the alternative splicing of LncPTEN1, resulting in significantly elevated LncPTEN1 expression in normal lung cells. Clinical analyses across multiple patient cohorts demonstrate that low LncPTEN1 expression strongly correlates with poor patient survival and increased metastas2025-01-01T00:00:00Z2025 Oct2026-06-02T22:30:37.675Z2026-04-21T03:14:09.841ZS-EPMC121671244052124310.1016/j.ncrna.2025.05.011